Show cover of MedEdTalks - Ophthalmology

MedEdTalks - Ophthalmology

MedEdTalks Ophthalmology is a continuing medical education podcast for physicians to allow them to learn while on the go and obtain CME credits. This show will focus in on ophthalmology topics, such as nAMD and Diabetic Retinopathy and includes interviews with Dr. Rishi Singh from the Cole Eye Institute, Dr. Andrew Moshfeghi from the USC Roski Eye Institute, Dr. Dilsher Dhoot from California Retina Consultants, Dr. Theodore Leng from Byers Eye Institute at Stanford, Dr. Nathan Steinle from California Retina Consultants, Dr. Nancy Holekamp from Washington University School of Medicine and Dr. Arshad Khanani from University of Nevada.

Tracks

Targeting Angiopoietin-2 in DME: Efficacy and Safety Data With Drs. Carl Regillo and Nancy Holekamp
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Nancy Holekamp discuss the efficacy and safety of therapies targeting Ang-2 in DME.
16:41 05/31/2022
Targeting Angiopoietin-2 in nAMD: Efficacy and Safety Data With Drs. Carl Regillo and Arshad Khanani
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Arshad Khanani discuss the efficacy and safety of therapies targeting Ang-2 in nAMD.
20:13 05/31/2022
The Tie2 Pathway and Its Role in the Pathophysiology of Retinal Vascular Disease With Drs. Carl Regillo and Judy Kim
The angiopoietin/Tie2 pathway is an attractive therapeutic target for the management of retinal and choroidal vascular diseases, as it has been identified to play a role in vascular permeability and angiogenesis within the eye. Several therapies targeting this pathway have been investigated, and the FDA recently approved the first agent that inhibits both the angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Dual inhibition of these 2 pathways has the potential to enhance visual acuity outcomes while lowering the treatment burden. In this podcast, Dr. Carl Regillo and Dr. Judy Kim discuss the Tie2 pathway and its role in the pathophysiology of retinal vascular diseases.
13:01 05/31/2022
Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 4 Recap with Dr. Steven Ferrucci
Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 4.
05:06 05/10/2022
Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 3 Recap with Dr. Rishi Singh
Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 3.
04:11 05/10/2022
Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 2 Recap with Dr. Steven Ferrucci
Steven Ferrucci, OD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 2.
05:30 05/10/2022
Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 1 Recap with Dr. Rishi Singh
Rishi P. Singh, MD, provides an overview of the CE-certified ePublication, Retinal Disease Digest: Opportunities for Optometrists Volume 1, Issue 1.
04:18 05/10/2022
Multidisciplinary Strategies to Reduce the Burden of Ocular Toxicities in Myeloma With Drs. Sagar Lonial and Asim V. Farooq
In this podcast, expert clinicians will discuss best practices for reducing ocular toxicities in myeloma patients through the multidisciplinary team.
15:26 01/31/2022
Managing Ocular Toxicities in Patients on Multiple Myeloma Therapy With Drs. Sagar Lonial and Asim V. Farooq
In this podcast, expert clinicians will discuss strategies to mitigate and manage ocular toxicities related to multiple myeloma therapy.
16:50 01/31/2022
Frequency and Identification of Ocular Toxicities Associated With Myeloma Therapy With Drs. Sagar Lonial and Bennie Jeng
In this podcast, expert clinicians will discuss the frequency and identification of ocular toxicities of patients on myeloma therapy.
13:21 01/31/2022
Mechanisms Underlying Ocular Toxicities in Cancer Therapy With Drs. Bennie Jeng and Sagar Lonial
In this podcast, expert clinicians will discuss the mechanisms behind ocular toxicities that have been associated with antibody drug conjugates used for cancer treatment.
14:07 01/31/2022
Gel Stent Failure
This educational activity will review best practices regarding the use of gel stents in the treatment of glaucoma.
24:41 12/28/2021
Recent Developments in the Role of Optical Coherence Tomography Angiography in the Management of Glaucoma
In this podcast, John Samples, MD, and Brian Francis, MD, discuss the current and evolving role of optical coherence tomography angiography in the management of glaucoma.
16:46 12/16/2021
Cyclophotocoagulation in Glaucoma: Recent Developments and Best Practices
In this podcast, John Samples, MD, and Michael Giovigno, MD, review best practices for the use of cyclophotocoagulation in the management of glaucoma.
30:17 12/16/2021
Cerebrospinal Fluid Pressure and Glaucoma
In this podcast, John R. Samples, MD, and Russell Swan, MD, discuss the relevance of cerebrospinal fluid pressure in the management of glaucoma.
24:26 12/16/2021
Management of Glaucoma During the COVID Pandemic
This educational activity will review best practices in the management of patients with glaucoma.
21:43 11/09/2021
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 4
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 4
05:25 09/27/2021
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 3
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 3
04:40 08/18/2021
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 2
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions Volume 10, Issue 2
04:53 07/30/2021
Enhancing Outcomes in OSD Using Combination Therapy and New Drug Formulations, With Drs. Lisa Nijm and John Sheppard
This educational podcast will review the use of combination therapy, new drug formulations, and procedures to improve outcomes for patients with ocular surface disease.
24:30 07/29/2021
Differentiating New Strategies for Treating OSD: A Look at the Evidence With Drs. Lisa Nijm and Eric Donnenfeld
In this educational podcast, experts discuss emerging therapies for their ability to improve outcomes in patients with ocular surface disease. Faculty also review the safety and efficacy data to support new and emerging treatment options for OSD.
35:30 07/13/2021
Managing Ocular Surface Disease in Special Patient Populations With Drs. Lisa Nijm and Vance Thompson
This educational podcast will review important considerations for the diagnosis and management of ocular surface disease (OSD) in special patient populations. Faculty will provide pearls for preventing and managing OSD in individuals at elevated risk, including those undergoing ocular surgery, those with glaucoma or diabetes, as well as individuals on medications known to disrupt the ocular surface. 
27:50 07/13/2021
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions, Volume, 10, Issue 1
Recap with Dr. Rishi Singh: An Overview of Intravitreal Interventions, Volume, 10, Issue 1
08:38 07/09/2021
Port Delivery System With Ranibizumab, With Nancy M. Holekamp, MD, and Arshad M. Khanani, MD, MA
In this podcast, expert clinicians will discuss best practices regarding the use of Port Delivery System with ranibizumab.
18:21 07/01/2021
Achieving Vascular Stability through Inhibition of Ang-2 in AMD and DME, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACS
In this podcast, expert clinicians will discuss achieving vascular stability through inhibition of Ang-2. To obtain CME credit, go here: https://tinyurl.com/y58538ef 
18:27 07/01/2021
Emerging Delivery Systems in Neovascular Retinal Disease: Focus on Gene Therapy, With Nancy M. Holekamp, MD, and Arshad M. Khanani, MD, MA
In this podcast, expert clinicians will discuss emerging gene therapies for AMD and DME.   To obtain CME credit, go here: https://tinyurl.com/yusxpn44 
19:15 06/30/2021
Emerging Delivery Systems in Neovascular Retinal Disease: Focus on Devices, With Nancy M. Holekamp, MD, and Carl D. Regillo, MD, FACS
In this podcast, expert clinicians will discuss emerging delivery system devices in neovascular retinal disease.   To obtain CME credit, please go here: https://tinyurl.com/thma9fwp
15:26 06/30/2021
Curbside Consults on Retinal Vein Occlusion Management: Treating RVO Early to Improve Outcomes
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng assess the effect of treating RVO early in its course for the improvement of visual outcomes.
20:59 06/02/2021
Curbside Consults on Retinal Vein Occlusion Management: Use of Imaging in the Diagnosis of RVO
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and Christina Weng discuss the current use of imaging and biomarkers in the diagnosis as well as prognosis of RVO.
22:14 06/02/2021
Curbside Consults on Retinal Vein Occlusion Management: Use of Imaging in Monitoring Treatment Response in RVO
Retinal vein occlusions (RVOs) are the second most common retinal vascular disorder after diabetic retinopathy. The early and accurate diagnosis of RVO is paramount so that therapy can be initiated in a timely manner to prevent vision decline. Newer imaging technologies integrated into current diagnostic algorithms are aiding in the diagnosis of RVO and guiding therapy. Further, significant visual and anatomic improvements have been demonstrated with anti-vascular endothelial growth factor (VEGF) therapies in patients with central or branch RVO-related macular edema, and refinement of treatment protocols have the potential to further enhance outcomes as well as reduce treatment burden. In this curbside consult, Drs. Carl Regillo and David Eichenbaum examine innovations in imaging that can improve the monitoring of treatment response in patients with RVO.
18:35 06/02/2021